标签归档：dgn

DGN462

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DGN462 

DGN462 是一种有效的 DNA 烷基化剂，具有抗肿瘤活性，如抗急性髓系白血病 (AML)。DGN462 可以作为 ADC 毒素分子合成 ADC。

DGN462

DGN462 Chemical Structure

CAS No. : 1394079-41-4

规格 是否有货
5 mg 询价
10 mg 询价

* Please select Quantity before adding items.

生物活性

DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs)[1].

体外研究
(In Vitro)

DGN462 is a member of the DNA-alkylating indolinobenzodiazepine pseudodimers (IGNs) class[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

942.13

Formula

C53H59N5O9S
CAS 号

1394079-41-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hicks SW, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DGN549-C

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DGN549-C 

DGN549-C 由可分裂的 ADC 连接物 valine-alanine (va) 和 PBD 二聚体组成。DGN549 是一种新型的 DNA 烷基化试剂的有效载荷，可用于合成抗体-药物偶联物 (ADCs)。

DGN549-C

DGN549-C Chemical Structure

CAS No. : 2058075-34-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-drug conjugates (ADCs)[1].

IC50 & Target[1]

Traditional Cytotoxic Agents

 

分子量

1100.18

Formula

C60H61N9O12
CAS 号

2058075-34-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chen Bai, et al. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates With an Improved Therapeutic Index as Compared With Lysine Conjugation. Bioconjug Chem

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

sulfo-DGN462 sodium

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

sulfo-DGN462 sodium 

sulfo-DGN46 sodium 在培养基和血浆中可以降解为 DGN462。DGN462 是一种有效的 DNA 烷基化剂，具有抗肿瘤活性，如抗急性髓系白血病 (AML)。

sulfo-DGN462 sodium

sulfo-DGN462 sodium Chemical Structure

CAS No. : 1401203-09-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML)[1].

体外研究
(In Vitro)

DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs). DGN462 is a member of the DNA-alkylating indolinobenzodiazepine pseudodimers (IGNs) class[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1046.19

Formula

C53H60N5NaO12S2
CAS 号

1401203-09-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hicks SW, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DGN549-L

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DGN549-L 

DGN549-L 是一种 DNA 烷基化剂，可用于赖氨酸残基的抗体偶联。DGN549-L 可用于抗体-药物偶联物 (ADC) 的合成。

DGN549-L

DGN549-L Chemical Structure

CAS No. : 1884276-68-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

DGN549-L is a DNA alkylator and can be utilized for antibody conjugation at lysine residues. DGN549-L can be used in the synthesis of antibody-drug conjugates (ADCs)[1].

分子量

1075.13

Formula

C58H58N8O13
CAS 号

1884276-68-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Bai C, et al. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. Bioconjug Chem. 2020;31(1):93-103.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sulfo-SPDB-DGN462

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sulfo-SPDB-DGN462 

Sulfo-SPDB-DGN462 是 ADC 的药物连接偶联物。Sulfo-SPDB-DGN462 由毒素分子 DGN462 (HY-101150) 偶联到可裂解的Sulfo-SPDB linker。DGN462 是一种有效的DNA 烷基化剂，具有抗肿瘤活性，如急性髓系白血病 (AML)。

Sulfo-SPDB-DGN462

Sulfo-SPDB-DGN462 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML)[1].

IC50 & Target

Maytansinoids

 

分子量

1251.40

Formula

C61H66N6O17S3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hicks SW, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sulfo-SPDB-DGN462

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sulfo-SPDB-DGN462 

Sulfo-SPDB-DGN462 是 ADC 的药物连接偶联物。Sulfo-SPDB-DGN462 由毒素分子 DGN462 (HY-101150) 偶联到可裂解的Sulfo-SPDB linker。DGN462 是一种有效的DNA 烷基化剂，具有抗肿瘤活性，如急性髓系白血病 (AML)。

Sulfo-SPDB-DGN462

Sulfo-SPDB-DGN462 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML)[1].

IC50 & Target

Maytansinoids

 

分子量

1251.40

Formula

C61H66N6O17S3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hicks SW, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sulfo-SPDB-DGN462

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sulfo-SPDB-DGN462 

Sulfo-SPDB-DGN462 是 ADC 的药物连接偶联物。Sulfo-SPDB-DGN462 由毒素分子 DGN462 (HY-101150) 偶联到可裂解的Sulfo-SPDB linker。DGN462 是一种有效的DNA 烷基化剂，具有抗肿瘤活性，如急性髓系白血病 (AML)。

Sulfo-SPDB-DGN462

Sulfo-SPDB-DGN462 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Sulfo-SPDB-DGN462 is a drug-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML)[1].

IC50 & Target

Maytansinoids

 

分子量

1251.40

Formula

C61H66N6O17S3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hicks SW, et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务